Vaderis Therapeutics | Biotech & Life Sciences | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Vaderis Therapeutics

Company Overview Backed By Recent Activity Similar Companies Startup DNA

Vaderis Therapeutics

Vaderis Therapeutics is a Swiss biopharmaceutical company focused on rare vascular diseases, developing VAD044 for Hereditary Hemorrhagic Telangiectasia (HHT)

Biotech & Life Sciences

Sector

Seed

Stage

Biopharmaceutical development

Model

01Company Overview

Vaderis Therapeutics is a Swiss biopharmaceutical company focused on rare vascular diseases, developing VAD044 for Hereditary Hemorrhagic Telangiectasia (HHT).

02Backed By2 investors

TCThe Column Group→OFOmega Funds→

03

Is this your company? Claim your profile

Startup Intelligence by F4F4 Research Engine

Recent Activity

FROM Omega Funds

Led/participated in Vaderis Therapeutics $152.5M Series B financing to initiate the global Phase 3 HEROIC study for hereditary hemorrhagic telangiectasia.

INVESTMENT·fiercebiotech.com

AUG 13, 2026

FROM The Column Group

TCGX co-led Vaderis Therapeutics' oversubscribed $152.5M Series B financing to fund the global Phase 3 HEROIC study.

INVESTMENT·biospace.com

AUG 11, 2026

04Similar Companies

PP

Prophylix Pharma

Biotech & Life Sciences

KP

KalVista Pharmaceuticals

Biotech & Life Sciences

C

Biotech & Life Sciences

OH

Biotech & Life Sciences

HT

Hemab Therapeutics

Biotech & Life Sciences

05Startup DNA

8

signals

Sectors
Business Model
Technology

Quick Reference

Sector

Biotech & Life Sciences